دورية أكاديمية
أعرض في EDS

Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.

التفاصيل البيبلوغرافية
العنوان: Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.
المؤلفون: van Essen MF; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands., Schlagwein N; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands., van den Hoven EMP; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands., van Gijlswijk-Janssen DJ; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands., Lubbers R; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., van den Bos RM; Faculty of Science, Department of Chemistry, Crystal and Structural Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands., van den Born J; Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands., Ruben JM; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands., Trouw LA; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., van Kooten C; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
مؤلفون مشاركون: COMBAT consortium; Division of Nephrology and Transplant Medicine, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
المصدر: European journal of immunology [Eur J Immunol] 2022 Apr; Vol. 52 (4), pp. 597-608. Date of Electronic Publication: 2022 Feb 17.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 1273201 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-4141 (Electronic) Linking ISSN: 00142980 NLM ISO Abbreviation: Eur J Immunol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: Weinheim : Wiley-VCH
Original Publication: Weinheim, Verlag Chemie GmbH.
مواضيع طبية MeSH: Complement C3-C5 Convertases*/metabolism , Properdin*/metabolism, Complement Activation ; Complement Membrane Attack Complex ; Complement Pathway, Alternative ; Humans ; Necrosis
مستخلص: Properdin, the only known positive regulator of the complement system, stabilizes the C3 convertase, thereby increasing its half-life. In contrast to most other complement factors, properdin is mainly produced extrahepatically by myeloid cells. Recent data suggest a role for properdin as a pattern recognition molecule. Here, we confirmed previous findings of properdin binding to different necrotic cells including Jurkat T cells. Binding can occur independent of C3, as demonstrated by HAP-1 C3 KO cells, excluding a role for endogenous C3. In view of the cellular source of properdin, interaction with myeloid cells was examined. Properdin bound to the surface of viable monocyte-derived pro- and anti-inflammatory macrophages, but not to DCs. Binding was demonstrated for purified properdin as well as fractionated P2, P3, and P4 properdin oligomers. Binding contributed to local complement activation as determined by C3 and C5b-9 deposition on the cell surfaces and seems a prerequisite for alternative pathway activation. Interaction of properdin with cell surfaces could be inhibited with the tick protein Salp20 and by different polysaccharides, depending on sulfation and chain length. These data identify properdin as a factor interacting with different cell surfaces, being either dead or alive, contributing to the local stimulation of complement activation.
(© 2022 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.)
References: Infect Immun. 2011 Feb;79(2):724-31. (PMID: 21134964)
Immunol Rev. 2016 Nov;274(1):218-232. (PMID: 27782329)
J Biol Chem. 2012 Sep 7;287(37):31471-81. (PMID: 22815489)
Annu Rev Immunol. 2010;28:131-55. (PMID: 19947883)
Sci Immunol. 2017 Apr 28;2(10):. (PMID: 28480349)
Clin Exp Immunol. 2017 May;188(2):183-194. (PMID: 28249350)
J Biol Chem. 2011 Feb 18;286(7):5359-67. (PMID: 21135110)
Front Immunol. 2019 Sep 04;10:2097. (PMID: 31552043)
Front Immunol. 2020 Mar 03;11:232. (PMID: 32194548)
Eur J Immunol. 2017 Mar;47(3):470-480. (PMID: 28105653)
Eur J Immunol. 2019 Oct;49(10):1457-1973. (PMID: 31633216)
Front Immunol. 2015 Feb 02;6:25. (PMID: 25699044)
Front Immunol. 2020 Jan 09;10:3030. (PMID: 31998312)
J Immunol. 1997 May 1;158(9):4444-51. (PMID: 9127010)
Am J Physiol Renal Physiol. 2008 Nov;295(5):F1397-403. (PMID: 18753294)
Front Immunol. 2013 Jan 17;3:412. (PMID: 23335922)
J Biol Chem. 1984 Apr 10;259(7):4582-8. (PMID: 6707020)
Clin Exp Immunol. 2006 Jun;144(3):485-93. (PMID: 16734618)
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E534-E539. (PMID: 28069958)
J Exp Med. 1975 Oct 1;142(4):856-63. (PMID: 1185108)
Immunobiology. 2010 Nov;215(11):932-40. (PMID: 20382442)
J Immunol. 2008 Mar 15;180(6):3964-8. (PMID: 18322205)
Front Immunol. 2019 Aug 22;10:2007. (PMID: 31507604)
Elife. 2020 Sep 10;9:. (PMID: 32909942)
J Immunol Methods. 2020 Apr;479:112748. (PMID: 31958452)
Front Immunol. 2020 Nov 10;11:572562. (PMID: 33240263)
Front Immunol. 2020 Aug 07;11:1643. (PMID: 32849563)
J Immunol. 2007 Aug 15;179(4):2600-8. (PMID: 17675523)
Mol Immunol. 2011 May;48(9-10):1121-7. (PMID: 21397947)
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9023-8. (PMID: 18579773)
N Engl J Med. 2001 Apr 5;344(14):1058-66. (PMID: 11287977)
Front Immunol. 2019 Jun 17;10:1350. (PMID: 31263464)
Am J Physiol Renal Physiol. 2016 Jun 1;310(11):F1308-16. (PMID: 26984957)
Trends Immunol. 2008 Aug;29(8):380-7. (PMID: 18602340)
Biochem J. 1987 Apr 15;243(2):507-17. (PMID: 3307764)
Mol Immunol. 2008 Oct;45(16):4048-56. (PMID: 18692243)
Mol Immunol. 2016 Jan;69:62-9. (PMID: 26675068)
J Immunol. 2008 Jun 1;180(11):7613-21. (PMID: 18490764)
J Immunol. 2012 Sep 1;189(5):2606-13. (PMID: 22851705)
Elife. 2021 Jan 22;10:. (PMID: 33480354)
Kidney Int. 2018 Dec;94(6):1141-1150. (PMID: 30322716)
فهرسة مساهمة: Keywords: Alternative pathway; Complement system; Dendritic cells; Macrophages; Properdin; Viable/death cells
المشرفين على المادة: 0 (Complement Membrane Attack Complex)
11016-39-0 (Properdin)
EC 3.4.21.- (Complement C3-C5 Convertases)
تواريخ الأحداث: Date Created: 20220129 Date Completed: 20220407 Latest Revision: 20220729
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9303752
DOI: 10.1002/eji.202149259
PMID: 35092629
قاعدة البيانات: MEDLINE
الوصف
تدمد:1521-4141
DOI:10.1002/eji.202149259